Helping clinicians investigate sooner and plan next steps with confidence
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the availability of the IDEXX Cancer Dx™ Panel in the United Kingdom, beginning with early detection of lymphoma in at-risk* dogs. The blood test can be added to panels for sick pets and integrated into regular wellness screenings, with veterinarian pricing starting from £22.50† and results available to UK practices within 3–5 business days.
Cancer remains a leading cause of canine death, with 1 in 4 dogs expected to be diagnosed with cancer in their lifetime.1 Lymphoma, one of the most common cancers, accounts for nearly a quarter of new cancer diagnoses.2 Treatment for canine lymphoma may help extend the lifespan and improve the quality of life for affected dogs, highlighting the critical need for early detection and intervention.
Research indicates that 71% of pet owners in the UK are interested in having a cancer screening test for their pet,3 signalling strong demand for proactive, wellness care.
That momentum is already visible in practice. Since the test launched in North America in 2025, nearly 6,000 veterinary practices across the United States and Canada have integrated the test into diagnostic and wellness workflows.4 The test can detect a lymphoma signal up to eight months before clinical signs appear5– helping clinicians investigate sooner and plan next steps with confidence.
“Building on more than 40 years of IDEXX’s leadership in veterinary research and technology development, IDEXX Cancer Dx is an important advancement to deliver unmatched diagnostic insights,” said Jay Mazelsky, President and Chief Executive Officer of IDEXX. “As leaders in key cancer diagnostic categories, like pathology and imaging, we continue to innovate technologies that can redefine how veterinarians approach cancer detection and monitoring in pets. We’re proud to be at the forefront of early cancer detection in dogs and delighted to expand access to reliable cancer testing in the UK.”
The IDEXX Cancer Dx Panel with lymphoma testing features:
- Accuracy: 79% sensitivity and 99% specificity yield results that can be used with confidence for both sick dogs and in routine preventative care for at-risk dogs.6
- Simplicity: Designed to fit seamlessly into existing veterinary workflows, clinicians can add IDEXX Cancer Dx to diagnostic and wellness panels using a single blood draw.
- Actionable next steps: IDEXX Cancer Dx delivers qualitative results for lymphoma. In many cases, B-cell and T-cell phenotype classification will be provided with positive results.7
- Treatment Monitoring: Early data shows that for patients with a positive Cancer Dx result at diagnosis, repeated testing can monitor remission during CHOP chemotherapy, a common treatment for canine lymphoma.8
- Personalised guidance and comprehensive support: Every IDEXX Cancer Dx result comes with access to IDEXX Medical Consultants, including board-certified oncologists and internists, along with pet-owner education materials and resources to support client communications.
- Deeper insights: IDEXX Preventative Care, a comprehensive portfolio of products and services supporting veterinarians in preventative care, now includes IDEXX Cancer Dx testing, unlocking additional insights for at-risk dogs.
With IDEXX Cancer Dx testing, general practitioners can now support a clinical diagnosis of lymphoma earlier than traditional diagnostics.6 Its ease of integration makes it an essential tool for practices committed to proactive cancer management.
Over the next three years, IDEXX plans to expand the Cancer Dx Panel to cover the majority of canine cancer cases, transforming cancer detection, and enabling earlier intervention. The IDEXX Cancer Dx lymphoma test is currently available to veterinary practices in the United Kingdom through the IDEXX Reference Laboratories service. For more information, visit the IDEXX Cancer Dx testing web page.
